## China Pharma Firm Accused of Ghost Patients, Fake Trials
Whispers from within the Chinese pharmaceutical industry point to widespread fraudulent practices involving clinical trials. A prominent domestic firm, reportedly specializing in oncology drugs, is under intense scrutiny for allegedly fabricating patient data and creating 'ghost patients' to inflate trial success rates. Sources suggest that investigators have uncovered evidence of sham trials, where patient records were systematically falsified to meet regulatory submission requirements for new drug approvals. This alleged deception not only undermines patient safety by potentially fast-tracking unsafe or ineffective drugs to market but also distorts the entire drug approval process. The implications for public health and the credibility of China's rapidly growing pharmaceutical sector are immense, potentially leading to significant regulatory crackdowns and international distrust.
---
- **Source**: 
- **Sector**: The Lab
- **Tags**: pharmaceutical_fraud, china, clinical_trials, regulatory_affairs
- **Credibility**: unverified
- **Published**: 2026-02-28 13:27:30
- **ID**: 791
- **URL**: https://whisperx.ai/en/intel/791